Biolegend, Inc.
San Diego, CA Part of Revvity Inc.
- UEI
- WVJUG294HEM6
- CAGE
- 4PM02
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Revvity Inc.
Parent
XURJMC9NS4L3
- Biolegend, Inc. WVJUG294HEM6
-
Revvity Inc.
Parent
XURJMC9NS4L3
- SAM.gov registration date
- Physical address
- 8999 Biolegend Way, San Diego, CA 92121, USA
- Website
- biolegend.com
- Founded
- 2002
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Totalseq-d human heme oncology cocktail biolegend INC:1135351 [26-004804] | Office of Logisitics and Acquisition Operations | $16,488 | |
| Biological and reagent material - biolegend flow cytometer antibodies | National Institute on Aging | $14,042 | |
| [25-014521]NIH nhlbi laboratory of immune regulatory genomics and epigenomics requires total SEQ antibody cocktails… | National Heart Lung and Blood Institute | $10,493 | |
| Biolegend totalseq-c reagents | National Heart Lung and Blood Institute | $48,965 | |
| [25-012698] the lab requires antibodies in order to for immune cell distribution and function in sleep study. | National Heart Lung and Blood Institute | $23,027 |
About Biolegend, Inc.
Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and diagnostic products headquartered in San Diego, California, operates as a prime contractor supplying specialized research materials to federal agencies on full-and-open purchase orders with no small business set-asides. Biolegend is a subsidiary of Revvity Inc., a publicly traded life sciences company, and competes entirely outside set-aside categories, emphasizing differentiated product capability rather than SBA designations.
Biolegend's federal footprint centers on antibody and reagent supply to the National Institutes of Health, driven by the company's proprietary TotalSeq and flow cytometry platforms. Recent representative awards include a $16.5 thousand purchase order from the NIH Clinical Center (May 2026) for TOTALSEQ-D Human Heme Oncology Cocktail reagents, a $56.8 thousand order from the National Institute of Allergy and Infectious Diseases (January 2025) for Alexa Fluor 700 and Brilliant Violet-labeled antibodies, a $48.9 thousand delivery from the National Heart, Lung, and Blood Institute (September 2025) for TOTALSEQ-C reagents supporting single-cell genomics research, and a $100.6 thousand flow cytometry reagent supply contract with the Department of Veterans Affairs Veterans Integrated Service Network 22 (January 2023). Work spans immunology, oncology, hematology, infectious disease diagnostics (including COVID-19 research), and neuroscience applications, with all manufacturing performed in San Diego.
Customer concentration is heavily weighted toward HHS-NIH components, which account for approximately 79% of combined potential value. The National Institute of Allergy and Infectious Diseases dominates the footprint, carrying 58 awards worth $1.3 million combined potential value, followed by the National Heart, Lung, and Blood Institute (18 awards, $250 thousand), the National Institute on Aging (13 awards, $140 thousand), and the National Cancer Institute (10 awards, $150 thousand). Eighteen distinct federal agencies have placed awards, but the top five account for 60% of the award count. The NIH Clinical Center, National Cancer Institute, and National Institute of Dental and Craniofacial Research round out active NIH purchasing, with sporadic awards from other HHS agencies and the Veterans Health Administration. Biolegend sits on a single named vehicle — the Blanket Purchase Agreement HHSN263200800029B (28 task orders, $347 thousand combined potential value) — suggesting most federal purchasing flows through direct purchase orders rather than standing IDIQs or GWACs.
Activity has remained stable in recent years, with 13 awards in 2023, 8 in 2024, and 9 in 2025, averaging low single-digit millions annually. Combined obligated dollars across 201 awards total $2.6 million, representing 99% of combined potential value, indicating substantial payment completion and minimal backlog. Only one award ($16 thousand) reaches ultimate completion within the next twenty-four months, presenting minimal recompete exposure. Biolegend's supply-chain position — sole-source supplier of oligonucleotide-tagged antibodies compatible with 10X Genomics platforms and other single-cell sequencing technologies — creates switching costs and technical barriers to entry that insulate the vendor from commodity competition. Prime work dominates at 99% of awards (199 of 201), with minimal subcontract footprint; two documented sub-awards to Parsons Government Services Inc. (July 2024) for research support and operations maintenance field support indicate rare use as a materials supplier on larger primes rather than a core teaming partner. Award values cluster in the $10 thousand to $60 thousand range, consistent with simplified acquisition procedures and catalog-item biomedical procurement, with no named contract vehicles, no IDVs, and no visible seat on broader civilian or defense IT platforms.
Quick answers
What is Biolegend, Inc.'s UEI?
Biolegend, Inc.'s Unique Entity ID (UEI) in SAM.gov is WVJUG294HEM6.
What is Biolegend, Inc.'s CAGE code?
Biolegend, Inc.'s CAGE code is 4PM02.
What is Biolegend, Inc.'s primary NAICS code?
Biolegend, Inc.'s primary NAICS code is 325414 (Biological Product (except Diagnostic) Manufacturing).
Where is Biolegend, Inc. located?
Biolegend, Inc.'s physical address in SAM.gov is 8999 Biolegend Way, San Diego, CA 92121, USA.
Is Biolegend, Inc. registered in SAM.gov?
Yes. Biolegend, Inc.'s SAM.gov registration is active through July 28, 2027.
Who is Biolegend, Inc.'s parent company?
Biolegend, Inc. is part of Revvity Inc.
What is Biolegend, Inc.'s most recent federal award?
Biolegend, Inc.'s most recent federal contract award is Totalseq-d human heme oncology cocktail biolegend INC:1135351 [26-004804] (75N98026P00452), from Office of Logisitics and Acquisition Operations, on May 7, 2026.
On GovTribe
See Biolegend, Inc.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors